Head-to-head · Cost-Efficiency Index
NuviaRx vs NexLife
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NuviaRx
Cost-first shoppers who want the lowest 'starting' price on paper, if you're willing to prepay a full year.
Visit NuviaRxNexLife
Cost-first shoppers who want wanting a genuinely flat, dose-independent price and willing to prepay a multi-month term for the lowest advertised rate.
Visit NexLifeThe verdict
NuviaRx takes it, leading the Cost-Efficiency Index 64 to 63. NuviaRx is a compounded GLP-1 telehealth platform advertising semaglutide from $140/mo and tirzepatide from $170/mo, but both figures require purchasing a full annual plan upfront no month-to-month pricing is published anywhere on the site. NexLife still earns a C — Cost-first shoppers who want wanting a genuinely flat, dose-independent price and willing to prepay a multi-month term for the lowest advertised rate.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs NuviaRx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NuviaRx | NexLife |
|---|---|---|
| Cost-Efficiency Index | 64/100 | 63/100 |
| Semaglutide / mo | $140/mo (all doses, annual plan, compounded) | $165/mo (all doses, compounded) |
| Tirzepatide / mo | $170/mo (all doses, compounded) | $215/mo (all doses, compounded) |
| Semaglutide / yr (modeled) | $1,680 | $1,980 |
| Tirzepatide / yr (modeled) | $2,040 | $2,580 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #179 | #185 |
NuviaRx
64/100Where the value is
- Genuinely flat pricing across all doses within the annual plan, with consultation and monthly check-ins bundled in
- No membership fees or dose-escalation surcharges disclosed
- Free home delivery included; cancel-anytime language present despite the annual-prepay framing
The tradeoffs
- The advertised '$140/$170 starting' price is gated behind a full annual prepay — no month-to-month rate is published anywhere on the site, so the headline figure is not accessible the way it reads
- No compounding pharmacy is named — only described generically as 'a licensed 503A compounding pharmacy'
NexLife
63/100Where the value is
- Flat pricing confirmed at every dose for both drugs — no per-mg escalation during titration, unlike most compounded competitors in this batch
- LegitScript certified with a named medical director (Adam Kennah, M.D.)
- States every batch undergoes independent third-party testing for potency, sterility, pH, and endotoxin levels
The tradeoffs
- The commonly advertised '$186/mo' tirzepatide headline requires a 12-month commitment; the true no-commitment month-to-month price is $215/mo — about 16% more
- No individual compounding pharmacy is named, only 'LegitScript-certified, NABP-accredited' pharmacies generically
Regulatory note: the FDA issued a warning letter to Nexlife Inc. dba Nexlife in June 2026. We still list and link to NexLife; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.